• By ICR Secretariat
  • Posted Thursday, December 1, 2022

FDA grants speedy review to Sarepta’s Duchenne gene therapy

https://www.biopharmadive.com/news/fda-priority-review-sarepta-duchenne-gene-therapy/637366/

The Food and Drug Administration has started the first regulatory review of a gene therapy for Duchenne muscular dystrophy, the treatment’s developer, Sarepta Therapeutics, announced on Monday